Second US FTC staff report says Big 3 PBMs significantly marked up HIV, cancer drugs
MLex Summary: The Federal Trade Commission published a second interim staff report on the prescription drug middleman industry, which focuses on pharmacy benefit managers’ influence over specialty generic drugs and significant...To view the full article, register now.
Already a subscriber? Click here to view full article